Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Receivables (2018 - 2025)

Fate Therapeutics' Receivables history spans 9 years, with the latest figure at $916000.0 for Q4 2025.

  • For Q4 2025, Receivables fell 74.12% year-over-year to $916000.0; the TTM value through Dec 2025 reached $916000.0, down 74.12%, while the annual FY2025 figure was $916000.0, 74.12% down from the prior year.
  • Receivables reached $916000.0 in Q4 2025 per FATE's latest filing, up from $682000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $38.5 million in Q4 2022 to a low of $682000.0 in Q3 2025.
  • Average Receivables over 5 years is $7.2 million, with a median of $3.8 million recorded in 2024.
  • Peak YoY movement for Receivables: skyrocketed 500.06% in 2021, then tumbled 95.25% in 2023.
  • A 5-year view of Receivables shows it stood at $8.7 million in 2021, then skyrocketed by 343.52% to $38.5 million in 2022, then crashed by 95.25% to $1.8 million in 2023, then skyrocketed by 93.81% to $3.5 million in 2024, then crashed by 74.12% to $916000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Receivables are $916000.0 (Q4 2025), $682000.0 (Q3 2025), and $1.4 million (Q2 2025).